Third Rock Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
BiotechSouth San Francisco, US
Ivana Djuretic(Executive Officer, Director, Promoter)Yik Andy Yeung(Executive Officer, Director, Promoter)
Board seatJeffrey TongReid Huber· per SEC Form D · $55M raise · filed Apr 2024
BiotechBoston, US
Gleb Kuznetsov(Executive Officer, Director)Pierce Ogden(Executive Officer, Director)
BoardJory Bell(Director)Jeff Huber(Director)Steven Holtzman(Director)
Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+2 more
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossovervenBio PartnersVida Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.